Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/05/26
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE GrowthMarketBeat • 05/19/26
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data LoomsMarketBeat • 05/13/26
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthZacks Investment Research • 05/07/26
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/06/26
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial GuidanceBusiness Wire • 05/06/26
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.Business Wire • 04/30/26
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual MeetingBusiness Wire • 04/17/26
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026Business Wire • 04/15/26
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 04/08/26
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett SyndromeBusiness Wire • 04/07/26
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullbackProactive Investors • 03/25/26
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)Zacks Investment Research • 03/05/26
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EUZacks Investment Research • 03/04/26
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 03/02/26
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline KickerSeeking Alpha • 02/28/26